Back to Main

Faculty Detail    
Name DAVID WINSTON KIMBERLIN
 
Campus Address CHB 303 Zip 0011
Phone 205-934-5316
E-mail dkimberlin@uab.edu
Other websites
     


Faculty Appointment(s)
Appointment Type Department Division Rank
Primary  Pediatrics   Ped - Infectious Disease Professor
Center  General Clinical Research Center  Center for Outcomes & Effectiveness Res & Educ Professor
Center  Comprehensive Cancer Center  Comprehensive Cancer Center Professor

Biographical Sketch 
Dr. Kimberlin holds the Sergio Stagno Endowed Chair in Pediatric Infectious Diseases at the University of Alabama at Birmingham, where he is Co-Director of the Division of Pediatric Infectious Diseases. Dr. Kimberlin is Principal Investigator (PI) of the Collaborative Antiviral Study Group (CASG), and is the PI on the CASG’s four newly awarded contracts of $19.2M from NIH/NIAID/DMID to evaluate novel therapeutic and diagnostic opportunities for management of neonatal herpes simplex virus (HSV) disease and congenital cytomegalovirus (CMV) infection. These studies will involve approximately 20 academic medical centers in the Unites States and Great Britain, and will build upon previous CASG studies conducted by Dr. Kimberlin that have defined the standard of care for the treatment of neonatal HSV and congenital CMV infections. Other CASG investigations led by Dr. Kimberlin defined the worldwide management of infants with influenza disease during the 2009 H1N1 pandemic, and have investigated experimental therapies for neonatal enteroviral disease and laryngeal papillomatosis.

Dr. Kimberlin is Editor of the 2015 AAP Report of the Committee on Infectious Diseases (Red Book), and was Associate Editor for the 2009 and 2012 editions. He served as a member of the American Academy of Pediatrics (AAP) Committee on Infectious Diseases (COID) from 2005-2011. Dr. Kimberlin also is the AAP Red Book liaison to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), having served in this capacity for the past seven years. During this time, he has served as the COID liaison to six different ACIP Working Groups.

Dr. Kimberlin currently is President of the Pediatric Infectious Diseases Society (PIDS), which is the world's largest organization of professionals dedicated to the treatment, control, and eradication of infectious diseases affecting children. Dr. Kimberlin also serves as the Director of Subspecialty Medical Education for the UAB Department of Pediatrics. He has received numerous education awards, including the Ralph E. Tiller, M.D., Distinguished Faculty Award, recognizing the faculty member that the Senior Pediatric Resident class believes has contributed the most to their overall education and training experience (2003); the Argus Award nominee by second year medical students (Class of 2011) recognizing the Best Lecturer for the Reproductive Module (2009); the Argus Award nominee by third year medical students recognizing the Best Pediatrics Attending (2006, 2008, 2009); and selection by UAB Gold Humanism Honor Society third and fourth year medical students as faculty member who models the qualities of integrity, excellence, compassion, altruism, respect, and empathy in the care of patients (2011, 2012).



Society Memberships
Organization Name Position Held Org Link
Alpha Omega Alpha  Member   
American Academy of Pediatrics  Fellow   
Infectious Diseases Society of America  Fellow   
Pediatric Infectious Diseases Society  President    
Society for Pediatric Research  Member   

Research/Clinical Interest
Title
Antiviral therapies of pediatric infections
Description
Dr. David Kimberlin holds the Sergio Stagno Endowed Chair in Pediatric Infectious Diseases at the University of Alabama at Birmingham, where he is Co-Director of the Division of Pediatric Infectious Diseases. Dr. Kimberlin is Principal Investigator (PI) of the Collaborative Antiviral Study Group (CASG), and is the PI on the CASG’s four newly awarded contracts of $19.2M from NIH/NIAID/DMID to evaluate novel therapeutic and diagnostic opportunities for management of neonatal herpes simplex virus (HSV) disease and congenital cytomegalovirus (CMV) infection. These studies will involve approximately 20 academic medical centers in the Unites States and Great Britain, and will build upon previous CASG studies conducted by Dr. Kimberlin that have defined the standard of care for the treatment of neonatal HSV (N Engl J Med 2011, Pediatrics 2001) and congenital CMV (J Infect Dis 2008, J Pediatr 2003) infections. Other CASG investigations led by Dr. Kimberlin defined the worldwide management of infants with influenza disease during the 2009 H1N1 pandemic, and have investigated experimental therapies for neonatal enteroviral disease and laryngeal papillomatosis. From 2005-2011, Dr. Kimberlin was a member of the American Academy of Pediatrics (AAP) Committee on Infectious Diseases (COID). He was an Associate Editor of the AAP Report of the Committee on Infectious Diseases (Red Book) for the 2009 and 2012 editions, and has recently been named Editor for the 2015 Red Book. For the past six years, Dr. Kimberlin also has been the AAP Red Book liaison to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). During this time, he has served as the COID liaison to six different ACIP Working Groups. Dr. Kimberlin is President-Elect of the Pediatric Infectious Diseases Society (PIDS), which is the world's largest organization of professionals dedicated to the treatment, control, and eradication of infectious diseases affecting children. Dr. Kimberlin also serves as the Director of Subspecialty Medical Education for the UAB Department of Pediatrics.

Selected Publications 
Publication PUBMEDID
Kimberlin DW, Lakeman FD, Arvin AM, Prober CG, Corey L, Powell DA, Burchett SK, Jacobs RF, Starr SE, Whitley RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. J. Infect. Dis. 1996;174:1162-1167.

Kimberlin DW, Lin C-Y, Jacobs RF, Powell DA, Corey L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, Murguía de Sierra T, Weller S, Soong S-J, Kiell J, Lakeman FD, Whitley RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001;108:230-238.

Kimberlin DW, Lin C-Y, Jacobs RF, Powell DA, Frenkel L, Gruber WC, Rathore M, Bradley JS, Diaz PS, Kumar M, Arvin AM, Gutierrez K, Shelton M, Weiner LB, Sleasman JW, Murguía de Sierra T, Soong S-J, Kiell J, Lakeman FD, Whitley RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. The natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics 2001;108:223-229.

Kimberlin DW, Lin C-Y, Sanchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RF, Vaudry W, Kiell JM, Soong SJ, Whitley RJ, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Effect of ganciclovir on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: A randomized, controlled trial. J. Pediatr. 2003;143:16-25

Kimberlin DW, Rouse DJ: Genital herpes. N. Engl. J. Med. 2004;350(19):1970-1977.

DeVincenzo JP, Hall CB, Kimberlin DW, Sanchez PJ, Rodriguez WJ, Jantaush BA, Corey L, Kahn JS, Englund JA, Suzich JA, Palmer-Hill FJ, Branco L, Johnson S, Patel NK, Piazza FM: Surveillance of clinical respiratory syncytial virus (RSV) isolates for palivizumab resistant mutants. J. Infect. Dis. 2004;190:975-978.

Bradford RD, Cloud G, Lakeman AD, Boppana S, Kimberlin DW, Jacobs R, Demmler G, Sanchez P, Britt W, Soong SJ, Whitley RJ, and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J. Infect. Dis. 2005;191:227-233.

Acosta EP, Brundage RC, King JR, Griffin J, Cloud GA, Whitley RJ, Kimberlin DW, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid formulation of valganciclovir. Clin. Pharmacol. Therapeut. 2007;81:867-872.

Kimberlin DW, Whitley RJ: Varicella-zoster virus vaccine for the prevention of herpes zoster. N. Engl. J. Med. 2007;356:1338-1343.

Acosta EP, Brundage RC, King JR, Griffin J, Cloud GA, Whitley RJ, Kimberlin DW, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid formulation of valganciclovir. Clin. Pharmacol. Therapeut. 2007;81:867-872.

Kimberlin DW, Acosta EP, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud GA, Lakeman FD, Whitley RJ, for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group: A pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital CMV disease. J. Infect. Dis. 2008;197:836-845

Oliver SE Cloud GA, Sánchez PJ, Demmler GJ, Dankner W, Shelton M, Jacobs RJ, Vaudry W, Pass RF, Soong SJ, Whitley RJ, Kimberlin DW. Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J. Clin. Virol. 2009;46(S):S22-S26

Kimberlin DW, Jacobs RF, Weller S, van der Walt J-S, Heitman CK, Man CY, Bradley JS: Pharmacokinetics and safety of extemporaneously compounded valacyclovir oral suspension in pediatric patients from 1 month to 12 years of age. Clin. Infect. Dis. 2010;50:221-228

Kimberlin DW, Shalabi M, Abzug MJ, Lang D, Jacobs RF, Storch G, Bradley JS, Wade K, Ramilo O, Romero JR, Shelton M, Leach C, Guzman-Cottrill J, Robinson J, Abughali N, Englund J, Griffin J, Jester P, Cloud GA, Whitley RJ, for the NIAID Collaborative Antiviral Study Group: Safety of Oseltamivir Compared With the Adamantanes in Children Less Than 12 Months of Age. Pediatr. Infect. Dis. J. 2010;29:195-198

Acosta EP, Jester P, Gal P, Wimmer J, Wade J, Whitley RJ, Kimberlin DW, for the NIAID Collaborative Antiviral Study Group: Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 2010;202(4):563-566.

Kimberlin DW, Whitley RJ, Wan W, Powell DA; Storch G, Ahmed A, Palmer A, Sánchez PJ, Jacobs RJ, Bradley JS, Robinson JL, Shelton M, Dennehy PH, Leach C, Rathore M, Abughali N, Wright P, Frenkel LM, Brady RC, Van Dyke R, Weiner LB, Guzman-Cottrill J, McCarthy CA, Griffin J, Jester P, Parker M, Lakeman FD, Kuo H, Lee CH, Cloud GA, for the NIAID Collaborative Antiviral Study Group: Oral acyclovir suppression and neurodevelopment after neonatal herpes. N. Engl. J. Med. 2011;365(14):1284-1292.

Pinninti SG, Angara R, Feja KN, Kimberlin DW, Leach CT, Conrad DA, McCarthy CA, Tolan RW Jr: Neonatal herpes disease despite maternal antenatal antiviral suppressive therapy: A multicenter case series. J. Pediatr. 2012;161(1):134-138.  
 

Keywords
herpes simplex virus, cytomegalovirus, antiviral therapy, clinical trial design